As per the research report, the size of the Europe Atipamezole Market was valued at USD xx billion in 2021 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2026 during the forecast period 2021 to 2026.
Atipamezole is an α2 adrenergic receptor antagonist that is synthetic, suggested for the reversal of analgesic and sedative effects of medetomidine and dexmedetomidine in dogs. It has been researched in humans as well as a potential drug for Parkinson’s disease.
Atipamezole reverses the effects of analgesic and sedative drugs like xylazine, medetomidine, detomidine, and amitraz among others in animals. Also, in addition, it is used in treating imidazoline and amitraz decongestants toxicity among animals.
A decrease in sedative time of animals decreases the stay in-clinic, decreases hospitalization costs, reduces animal owner revisits and optimizes the time of staff. Also, increasing healthcare expenditure on animals and growing pet ownership is expected to propel the market growth. However, the market is constrained due to factors such as and stringent government regulations associated with the efficacy and safety of atipamezole and adverse effects of atipamezole among others.
This research report on the Europe Atipamezole Market has been segmented and sub-segmented into the following categories:
By Application:
By Route Of Administration:
By Country:
Europe has the second-largest market in the world for atipamezole by share. In the European region, Germany is expected to have the largest market share. Factors such as decreasing hospitalization costs and time optimization of staff are expected to propel the market growth in the region.
Key players operating in the Europe Atipamezole Market profiled in this report are Pfizer Inc., Orion Corporation, Alvetra & Werfft GmbH, CP Pharmaceuticals Ltd., Sogeval Laboratories, Inc., VetPharm, Inc., Ceva Sant Animale S.A., Dr. E. Graeub AG, A x ience SAS and Eli Lilly and Company among others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Anti-Sedatives
5.1.2 Others
5.1.3 Y-o-Y Growth Analysis, By Application
5.1.4 Market Attractiveness Analysis, By Application
5.1.5 Market Share Analysis, By Application
5.2 Route of Administration
5.2.1 Intramuscular
5.2.2 Intravenous
5.2.3 Subcutaneous
5.2.4 Intraperitoneal
5.2.5 Y-o-Y Growth Analysis, By Route of Administration
5.2.6 Market Attractiveness Analysis, By Route of Administration
5.2.7 Market Share Analysis, By Route of Administration
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Application
6.1.3.2 By Route of Administration
6.1.4 Market Attractiveness Analysis
6.1.3.1 By Application
6.1.3.2 By Route of Administration
6.1.5 Market Share Analysis
6.1.3.1 By Application
6.1.3.2 By Route of Administration
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Orion Corporation
8.3 Alvetra & Werfft GmbH
8.4 CP Pharmaceuticals Ltd.
8.5 Sogeval Laboratories, Inc.
8.6 VetPharm, Inc.
8.7 Ceva Sant Animale S.A.
8.8 Dr. E. Graeub AG
8.9 A x ience SAS
8.10 Eli Lilly and Company
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
